Man Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Man Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25,600	Closed	-$643K	–	2314
2022 Q3	$643K	Buy	+25,600	New	+$709K	﹤0.01%	1433
2022 Q2	–	Hold	0	–	–	–	1628
2021 Q4	–	Sell	-9,235	Closed	-$930K	–	2179
2021 Q3	$930K	Sell	9,235 -533	-5%	-$62.5K	﹤0.01%	1358
2021 Q2	$1.38M	Sell	9,768 -28,372	-74%	-$3.2M	﹤0.01%	1316
2021 Q1	$3.8M	Buy	38,140 +15,785	+71%	+$1.84M	0.02%	826
2020 Q4	$2.76M	Buy	+22,355	New	+$2.94M	0.01%	1072
2019 Q2	–	Sell	-43,543	Closed	-$3.72M	–	2042
2019 Q1	$3.72M	Sell	43,543 -26,757	-38%	-$2.22M	0.01%	1063
2018 Q4	$3.94M	Buy	+70,300	New	+$4.29M	0.02%	885

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Man Group's RETA Position: Q4 2022 in Review

Man Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 25,600 shares — an estimated $643K sold.

Man Group first reported a position in RETA in Q4 2018 and held it in 7 quarters. The position peaked at $3.94M in Q4 2018. 168 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

Man Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
Man Group sold 25,600 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $643K.
Man Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and held it in 7 quarters.
Man Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.94M in Q4 2018.
168 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.